Is serum troponin T a useful marker of myocardial damage in newborn infants with perinatal asphyxia?

2007 ◽  
Vol 96 (2) ◽  
pp. 181-184 ◽  
Author(s):  
S. Costa ◽  
E Zecca ◽  
G De Rosa ◽  
D De Luca ◽  
G Barbato ◽  
...  
Keyword(s):  
Troponin T ◽  
Perinatal Asphyxia ◽  
Newborn Infants ◽  
Myocardial Damage

scholarly journals Changes on Serum Troponin T Level before and after Taking Standard Therapy Medication in Heart Failure Patients

2020 ◽  
Vol 56 (1) ◽  
pp. 4
Author(s):  
Yen Yen Ari Indrawijaya ◽  
Suharjono Suharjono ◽  
Muhammad Aminuddin ◽  
Endang Retnowati ◽  
Gilang Mauladi Rahman
Keyword(s):  
Heart Failure ◽  
Cardiac Troponin ◽  
Standard Therapy ◽  
Troponin T ◽  
Severe Heart Failure ◽  
Myocardial Necrosis ◽  
Myocardial Damage ◽  
Symptom Improvement ◽  
Before And After ◽  
Difference Test

Patients with advanced heart failure (NYHA FC III and IV heart failure) had positive cardiac troponin levels in previous cohort studies. In heart failure, cardiac troponin T (cTnT) is a biomarker that is sensitive to myocardial damage, especially myocardial necrosis. However, there is still little information regarding changes in cTnT levels during standard therapy. This prospective observational study is aimed at evaluating changes in cTnT levels before and after the administration of standard therapy and evaluating symptom improvement before and after the administration of standard therapy in patients with severe heart failure. Measurement of cTnT levels and symptom improvement parameters before treatment was carried out on the first day of the inpatient and measurement after therapy was carried out on the last day of the inpatient. Sampling was done by consecutive sampling and found 30 patients in the inpatient room of the SMF Cardiovascular Disease, Dr. Soetomo Hospital, Surabaya during the months of May-July 2017. The results of the study obtained the average cTnT levels before therapy 33.48 + 31.88 pg/ml and the average cTnT levels after therapy 46.32 + 52.68 pg/ml. Based on the statistical difference test with the Wilcoxon sign-ranked test, there was no significant change in cTnT levels (p = 0.318). On the parameter of clinical symptom improvement, there was a significant decrease in pulse, respiratory rate, blood pressure, and mean arterial pressure before and after administration of therapy (p <0.05). There was no change in troponin T levels before and after the administration of therapy meant there was no worsening of myocardial necrosis.

scholarly journals Evaluation of subclinical cardiotoxicity in patients with breast cancer and arterial hypertension in two regimens of anthracycline-containing chemotherapy

2018 ◽  
Vol 15 (4) ◽  
pp. 59-64 ◽  
Author(s):  
A A Avalyan ◽  
E V Oshchepkova ◽  
M A Saidova ◽  
V N Shitov ◽  
E V Glazkova ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Arterial Hypertension ◽  
Cumulative Dose ◽  
Treatment Duration ◽  
Troponin T ◽  
Myocardial Damage ◽  
Breast Cancer Patients ◽  
Duration Of Treatment ◽  
Imaging Results ◽  
Group 2

Objective. To study of subclinical cardiotoxicity of two anthracycline-containing chemotherapy regimens in breast cancer patients with normotension and arterial hypertension. Materials and methods. 119 women (mean age 48,8±10,9 years) with triple negative breast cancer were enrolled. They are received one of two chemotherapy options that differed in the intensity and duration of treatment, including the total dose of anthracyclines. Depending on the chemotherapy option, the patients were divided into two groups: group 1 (n=54) - treatment duration ≤8 weeks, cumulative dose of doxorubicin was 200 mg/m2, group 2 (n=65) - treatment duration ≤16 weeks, the cumulative dose of doxorubicin was 320 mg/m2. Before and after chemotherapy completion of all patients, the level of troponin T (h.s.) and NT-proBNP was determined, and heart ultrasound was performed, 2D and 3D speckle tracking imaging. Results. In patients who received a higher cumulative dose of doxorubicin (group 2), a statistically significant increase in biomarkers of myocardial damage was observed (h.s. troponin T before chemotherapy was 7.8±0.5 pg/ml, after chemotherapy - 55.0±7.0 pg/ml, p

scholarly journals Prognostic Value of Combination of Cardiac Troponin T and B-Type Natriuretic Peptide after Initiation of Treatment in Patients with Chronic Heart Failure

2003 ◽  
Vol 49 (12) ◽  
pp. 2020-2026 ◽  
Author(s):  
Junnichi Ishii ◽  
Wei Cui ◽  
Fumihiko Kitagawa ◽  
Takahiro Kuno ◽  
Yuu Nakamura ◽  
...  
Keyword(s):  
Heart Failure ◽  
Chronic Heart Failure ◽  
Cardiac Troponin ◽  
Troponin T ◽  
Myocardial Damage ◽  
Left Ventricular ◽  
Functional Class ◽  
Cardiac Troponin T ◽  
Cardiac Events ◽  
Nyha Functional Class

Abstract Background: Recent studies have suggested that cardiac troponin T (cTnT) and troponin I may detect ongoing myocardial damage involved in the progression of chronic heart failure (CHF). This study was prospectively designed to examine whether the combination of cTnT, a marker for ongoing myocardial damage, and B-type natriuretic peptide (BNP), a marker for left ventricular overload, would effectively stratify patients with CHF after initiation of treatment. Methods: We measured serum cTnT, plasma BNP, and left ventricular ejection fraction (LVEF) on admission for worsening CHF [New York Heart Association (NYHA) functional class III to IV] and 2 months after initiation of treatment to stabilize CHF (n = 100; mean age, 68 years). Results: Mean (SD) concentrations of cTnT [0.023 (0.066) vs 0.063 (0.20) μg/L] and BNP [249 (276) vs 753 (598) ng/L], percentage increased cTnT (&gt;0.01 μg/L; 35% vs 60%), NYHA functional class [2.5 (0.6) vs 3.5 (5)], and LVEF [43 (13)% vs 36 (12)%] were significantly (P &lt;0.01) improved 2 months after treatment compared with admission. During a mean follow-up of 391 days, there were 44 cardiac events, including 12 cardiac deaths and 32 readmissions for worsening CHF. On a stepwise Cox regression analysis, increased cTnT and BNP were independent predictors of cardiac events (P &lt;0.001). cTnT &gt;0.01 μg/L and/or BNP &gt;160 ng/L 2 months after initiation of treatment were associated with increased cardiac mortality and morbidity rates. Conclusion: The combination of cTnT and BNP measurements after initiation of treatment may be highly effective for risk stratification in patients with CHF.

scholarly journals Effects of Implantable Cardioverter Defibrillator Implantation and Shock Application on Biochemical Markers of Myocardial Damage

2001 ◽  
Vol 47 (3) ◽  
pp. 459-463 ◽  
Author(s):  
Thomas Schlüter ◽  
Hannsjörg Baum ◽  
Andreas Plewan ◽  
Dieter Neumeier
Keyword(s):  
Ventricular Fibrillation ◽  
Implantable Cardioverter Defibrillator ◽  
Troponin T ◽  
Myocardial Damage ◽  
Normal Function ◽  
External Shocks ◽  
Icd Implantation ◽  
Cardioverter Defibrillator ◽  
Creatine Kinase Mb ◽  
Minor Myocardial Damage

Abstract Background: Implantable cardioverter defibrillator (ICD) implantation is a common approach in patients at high risk of sudden cardiac death. To check for normal function, it is necessary to test the ICD. For this purpose, repetitive induction and termination of ventricular fibrillation by direct current shocks is required. This may lead to minor myocardial damage. Cardiac troponin T (cTnT) and I (cTnI) are specific markers for the detection of myocardial injury. Because these proteins usually are undetectable in healthy individuals, they are excellent markers for detecting minimal myocardial damage. The objective of this study was to evaluate the effect of defibrillation of induced ventricular fibrillation on markers of myocardial damage. Methods: This study included 14 patients who underwent ICD implantation and intraoperative testing. We measured cTnT, cTnI, creatine kinase MB (CK-MB) mass, CK activity, and myoglobin before and at definite times after intraoperative shock application. Results: Depending on the effectiveness of shocks and the energy applied, the cardiac-specific markers cTnT and cTnI, as well as CK-MB mass, showed a significant increase compared with the baseline value before testing and peaked for the most part 4 h after shock application. In contrast, the increases in CK activity and myoglobin were predominantly detectable in patients who received additional external shocks. Conclusions: ICD implantation and testing leads to a short release of cardiac markers into the circulation. This release seems to be of cytoplasmic origin and depends on the number and effectiveness of the shocks applied.

Usefulness of high-sensitivity troponin T for the evaluation of patients with acute chest pain and no or minimal myocardial damage

2012 ◽  
Vol 164 (2) ◽  
pp. 194-200.e1 ◽  
Author(s):  
Juan Sanchis ◽  
Alfredo Bardají ◽  
Xavier Bosch ◽  
Pablo Loma-Osorio ◽  
Francisco Marín ◽  
...  
Keyword(s):  
Chest Pain ◽  
Troponin T ◽  
Acute Chest Pain ◽  
Myocardial Damage ◽  
High Sensitivity ◽  
High Sensitivity Troponin ◽  
High Sensitivity Troponin T

Impact of European Society of Cardiology/American College of Cardiology guidelines on diagnostic classification of patients with suspected acute coronary syndromes

2003 ◽  
Vol 40 (2) ◽  
pp. 156-160 ◽  
Author(s):  
P. O. Collinson ◽  
A. C. Rao ◽  
R. Canepa-Anson ◽  
S. Joseph
Keyword(s):  
Acute Coronary Syndromes ◽  
Troponin T ◽  
Myocardial Damage ◽  
District General Hospital ◽  
Relative Increase ◽  
World Health ◽  
Absolute Increase ◽  
Who Criteria ◽  
Diagnostic Strategies ◽  
Coronary Syndromes

Background: Assessment of the relative diagnostic accuracy of investigation strategies for patients with suspected acute coronary syndromes (ACS). Methods: A prospective observational study followed two groups of patients over a 3-month period in a UK district general hospital. Group one: all admissions with suspected ACS ( n = 576); group two: non-cardiac in-patients who were suspected of developing ACS ( n = 87). Both were investigated by full clinical history, examination and serial electrocardiographs (ECGs). Conventional World Health Organization (WHO) criteria for myocardial damage were compared with diagnosis based on cardiac troponin T (cTnT). Clinical discharge diagnosis based on conventional WHO criteria was compared with the review diagnosis based on measurement of cTnT. Results: Diagnosis based on WHO criteria missed 58 patients (8·7%) admitted with suspected ACS who had high risk unstable angina. Thirty-three patients (5% of all admissions) who were diagnosed as non-Q wave acute myocardial infarction (AMI) were found to have normal troponin values and to have been incorrectly classified as AMI. Conclusions: Diagnostic strategies based on WHO criteria are inaccurate. The measurement of cTnT in all patients with suspected ACS would have increased the number of those with a diagnosis of AMI by 58 (8·7%), while avoiding inaccurate diagnosis in 33 (5%), therefore producing an absolute increase of 25/663 (3·8%) but a relative increase of 58/138 (42%). In patients with a primary diagnosis of suspected ACS, the overall increase in patients with a diagnosis of AMI will be 55 (9·5%), a relative increase of 55/118 (46·6%) but an absolute increase of 36/576 (6·3%).

Sign in / Sign up

Export Citation Format

Share Document